Kevan Herold, MD

Professor of Immunobiology and of Medicine (Endocrinology)

Research Interests

Diabetes Mellitus, Type 1; Endocrine System Diseases; Immune System Diseases; Metabolism; Autoimmunity; Translational Medical Research

Public Health Interests

Immunology; Metabolism

Research Organizations

Immunobiology: Herold Lab | Human and Translational Immunology Program

Internal Medicine: Diabetes Research Center | Endocrinology: Fellowship Training | Rheumatic Diseases Research Core

NIH T32 Program

Yale Cancer Center: Cancer Immunology

Yale Stem Cell Center

Office of Cooperative Research

Research Summary

The work in our laboratory involves translational studies in human immunology, focused on Type 1 diabetes. We are carrying out clinical studies of new immune therapies, in particular humanized anti-CD3 monoclonal antibody, and study the metabolic and immunologic effects of these interventions on the disease process. We are studying the ability of this intervention to prevent the loss of insulin production that characterizes the disease and determining the optimal approach to use this and other immune treatments in the disease setting. We have identified a novel regulatory mechanism that we believe is involved in the patients’ response to anti-CD3 mAb and plan to expand these studies so that adoptive immune therapy can be performed without the need for systemic treatment of patients.

In addition, we are interested in developing new ways in which immune therapies can be combined with cellular and/or metabolic approaches to restore normal beta cell mass and function. We are testing whether immune interventions can lead to spontaneous restoration of beta cell mass and developing new approaches to stimulate beta cell regeneration. Our studies to address this goal involve studies in patients and in animal models of the disease.

Specialized Terms: Type 1 diabetes; Immune therapy; Autoimmunity

Extensive Research Description

The pathogenesis and treatment of autoimmune disease, in particular Type 1 diabetes.

Studies involve clinical trials with patients and investigations of the mechanism of action of immune therapies and the pathogenesis of disease in patients as well as in animal models when needed to address what cannot be studies in humans. Over the past 7 years, our lab has carried out trials of a humanized non-FcR binding anti-CD3 monoclonal antibody in patients and has studied the mechanism of drug action. These clinical studies have suggested novel mechanisms of immune regulation that are now to be addressed with new clinical studies.

Selected Publications

Full List of PubMed Publications

Edit this profile